Preview Newsletter
XARELTO Media Monitoring – Week of 01-29-16
-
Xarelto Lawsuit Plaintiffs Note More Than 4 Years Without An Available Antidote
Jan 23, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on Xarelto plaintiffs who have noted that the blood thinner has surpassed 4 years on the market, yet still has no corresponding antidote available from manufacturers. They claim that this shows reckless negligence by the drug’s manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of the Johnson & Johnson corporation). The Xarelto lawsuits consolidated in MDL No. 2592 have now undergone the selection of 40 cases for a bellwether trial pool, and further bellwether trial selection, which will prepare 4 cases to be heard in 2017. The MDL cases are housed in the Eastern District of Louisiana and are being overseen by the Honorable Judge Eldon Fallon. -
Wrongful Death Xarelto Lawsuit Filed By South Florida Resident Over Husband’s Fatal Bleed
Jan 27, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which has been filed against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) in which the plaintiff claims that Xarelto, a blood thinner they manufacture, caused the wrongful death of her husband. The lawsuit, filed by the widow, was listed under case number 9:14-cv-80831 before it was transferred to the Eastern District of Louisiana to become a part of multidistrict litigation No. 2592. The MDL is being overseen byJudge Eldon Fallon. -
Xarelto Lawsuit Plaintiffs Cite Multiple Studies Which Link Drug To Excessive Bleeding Concerns
Jan 29, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on multiple studies which help to support plaintiff arguments in recent Xarelto lawsuits. The results of these studies appear to highlight unsettling links between blood-thinning drug Xarelto and an increased risk for spontaneous and uncontrollable bleeding episodes in those taking it. -
Xarelto Blood Thinner MDL Reaches 2,400 Lawsuits
Jan 22, 2016 | Top Class Actions
By Ashley Vanover
Blood thinner lawsuits alleging patients suffered serious and life-threatening internal bleeding events after using the blood thinner Xarelto show no signs of slowing down, with 2,400 Xarelto lawsuits now pending in the multidistrict litigation. -
Have you or a loved one suffered from Xarelto complications?
Jan 24, 2016 | Law Offices of Ben C. Martin
Xarelto is the brand name for the blood-thinner Rivaroxaban, which is used to prevent blood clotting. It is an anticoagulant that works by blocking certain clotting proteins in blood. This drug is typically used to eliminate blood clotting when a patient is suffering from afflictions such as an irregular heartbeat (atrial fibrillation), after hip or knee replacement surgery, deep vein thrombosis (DVT), and pulmonary embolisms. -
Xarelto Bleeding Injury Lawsuit
Jan 24, 2016 | Cory Watson Attorneys
The attorneys at Cory Watson are helping families determine whether the prescription drug Xarelto is responsible for bleeding that shuts down the brain, lungs, kidneys, and other organs. Xarelto use is also linked to deadly hemorrhagic strokes and large hematomas. -
Lawsuit: Drug Maker Failed to Disclose Xarelto Bleeding Risk
Jan 25, 2016 | American Injury Attorney Group
Drug makers face allegations of negligence after a man died due complications family members claim were associated with the prescription blood thinner Xarelto. Attorneys handling the lawsuit allege that the drug makers were aware of a Xarelto bleeding risk, but failed to properly warn consumers or release all of its findings about the drug’s potentially harmful effects. Affected families are pursuing claims for compensation against the manufacturers of the blood thinner with the assistance of Xarelto attorneys. -
Act Now For Xarelto Suits: Time Running Out
Jan 25, 2016 | Colson Hicks Eidson
We have been keeping you up-to-date on the progress of the Xarelto multidistrict litigations, so we wanted to let you know that time is running out for any victims who have suffered injuries or lost loved ones due to this potentially harmful drug. -
Xarelto-Related Bleeding Events Such As Gastrointestinal (GI) Bleeds And Hemorrhages, As Well As Other Serious Side Effects
Jan 26, 2016 | Drug Injury Law
Xarelto® is the name under which Janssen Pharmaceuticals, Inc. markets a prescription anticoagulant medication generically called rivaroxaban. -
New Year Sees 400 More Lawsuits Added to Xarelto MDL
Jan 28, 2016 | LawyersandSettlements.com
By Heidi Turner
The new year has seen more than 400 Xarelto lawsuits added to the multidistrict litigation, with almost 3,000 lawsuits now consolidated for pretrial proceedings. Xarelto lawsuits allege patients given the blood thinner were not properly warned about the increased risk of bleeding events, nor that the newer-generation anticoagulant did not have an approved antidote. -
Xarelto Linked to Internal Bleeding Side Effects
Jan 29, 2016 | Wolf and Pravato
Xarelto (rivaroxaban) is a popular blood thinner, which may be linked with an increased risk of Xarelto internal bleeding. Janssen, Xarelto’s manufacturer, claims that over seven million people across the globe have been prescribed Xarelto. These patients use Xarelto to prevent dangerous blood clotting complications. -
European Medicines Agency (EMA) Questions Defective Device in Xarelto Trial
Jan 27, 2016 | Schmidt National Law Group
Even the European Medicines Agency (EMA) now questions the reliability of the largest Xarelto clinical trial, the ROCKET AF trial. The study granted the Food and Drugs Administration’s (FDA) approval to the famous blood thinner Xarelto in 2011, and involved more than 14,000 patients to test Xarelto safety on human patients. In this clinical trial, patients with Atrial fibrillation (AFib) were administered either Xarelto or Warfarin to prevent stroke to compare the effectiveness of both these medications. However, last month the EMA found that the results of the ROCKET AF trial may not be so reliable as they initially thought to be. Back in 2011 the FDA regulators warned about some bias found in the clinical trial, however, so it’s not the first time that ROCKET AF’s reliability is questioned. -
Senate Appoints New FDA Chief Amid Xarelto Concerns
Jan 27, 2016 | Righting Injustice
By Jennifer Walker-Journey
The U.S. Senate ha appointed Dr. Robert Califf to serve as the new chief of the Food and Drug Administration (FDA), making him the most powerful health regulator in the world. Califf replaces Margaret Hamburg. He previously served as the Deputy Commissioner.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Articles Below
ROCKET AF Trial
-
Xarelto Lawsuit Plaintiffs Note More Than 4 Years Without An Available Antidote
Jan 23, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on Xarelto plaintiffs who have noted that the blood thinner has surpassed 4 years on the market, yet still has no corresponding antidote available from manufacturers. They claim that this shows reckless negligence by the drug’s manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of the Johnson & Johnson corporation). The Xarelto lawsuits consolidated in MDL No. 2592 have now undergone the selection of 40 cases for a bellwether trial pool, and further bellwether trial selection, which will prepare 4 cases to be heard in 2017. The MDL cases are housed in the Eastern District of Louisiana and are being overseen by the Honorable Judge Eldon Fallon.
Plaintiffs involved in the lawsuits note the lack of antidote for the anticoagulant as a major issue. This missing antidote means that someone using Xarelto who becomes even slightly injured and bleeds will be in danger of uncontrollable bleeding. Physicians will be unable to clot their blood if they have the blood thinning drug in their system. In situations like these, doctors must resort to extreme life-saving tactics such as surgery to relieve pressure from pooling blood, or blood transfusions.
Though Xarelto manufacturers have reportedly been working on developing an antidote for their drug, it has been four years, and one has still not been released to market. Other traditional blood thinners came onto the market years earlier than Xarelto, and have an available antidote for consumers through vitamin K. When people taking traditional blood thinners are injured and begin to bleed, doctors can treat them with vitamin K to reverse the effects of their blood thinner and clot their blood. This seemingly small difference can actually be one that means life vs. death for patients in emergency situations.
Xarelto launched onto the market after its 2011 approval by the U.S. Food and Drug Administration. It was intended as a treatment to prevent deep vein thrombosis (DVT) or other blood clots for patients who were recovering after hip or knee replacement surgeries. Just a few months after this initial approval, it also became approved to treat patients suffering from atrial fibrillation heart conditions, as a preventative measure since these individuals are at increased risk for strokes.
When Xarelto was first available to the public, it was regarded as a revolutionary new-generation blood thinner because it did not require regular monitoring and dosage adjustments or a special diet. Many plaintiffs argue that Xarelto’s dosage (the only blood thinner to offer 1 pill per day dosing) is problematic as well. Now, after an alarming 2,800 federal lawsuits have been filed against the blood thinner, Xarelto has become widely considered one of the most dangerous blood thinners on the market.
Lawsuits surrounding the drug continue to increase in number. Those consolidated in MDL 2592 in Louisiana are also joined by another 550 cases which have formed a mass tort group in Philadelphia, PA. Despite this continuing increase in lawsuit numbers, however, Xarelto has remained at the top of the list of most frequently used blood thinners. Plaintiffs involved in today’s lawsuits indicate that drug manufacturers use misleading marketing tactics which focus on the benefits of the drug, but do not adequately inform the public of its potentially dangerous and life threatening side effects.
Attorney Joseph Osborne is currently working to help ensure that everyone negatively affected by Xarelto will have the opportunity to fully explore their legal rights. Those who suffered from adverse health events after taking the anticoagulant may be entitled to legal action and significant compensation. At this time, Attorney Osborne is offering free legal consultations for affected individuals.
To ask questions or request additional information on Xarelto litigation, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2813688#ixzz3yfUHpCK7
-
Wrongful Death Xarelto Lawsuit Filed By South Florida Resident Over Husband’s Fatal Bleed
Jan 27, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which has been filed against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) in which the plaintiff claims that Xarelto, a blood thinner they manufacture, caused the wrongful death of her husband. The lawsuit, filed by the widow, was listed under case number 9:14-cv-80831 before it was transferred to the Eastern District of Louisiana to become a part of multidistrict litigation No. 2592. The MDL is being overseen byJudge Eldon Fallon.
Initially, the lawsuit was filed in southern Florida by the widow of the deceased husband, who claims that Xarelto manufacturers failed to properly warn patients about the significant uncontrollable bleeding and side effect dangers she links to their anticoagulant. The plaintiff alleges that the drug was the cause of her husband's death, which occurred after he suddenly experienced an episode of uncontrollable internal bleeding which physicians were unable to clot.
Within court document details, the widow explains that her husband was prescribed Xarelto to treat his atrial fibrillation heart condition. The blood thinner was intended to prevent him from suffering any strokes, however, while using the drug, he suffered from a brain bleed called a subdural hemorrhage, which he passed away from after physicians were unable to get his brain bleed to stop.
In 2011, the U.S. Food and Drug Administration approved Xarelto, and it launched onto the market as a revolutionary, new-generation blood thinner. Traditional blood thinners require consumers to go through frequent monitoring and dosage adjustments, as well as specific diets, where Xarelto required none of these. These benefits, which many plaintiffs say were strategically overemphasized, likely helped customers to overlook a very serious issue: Xarelto manufacturers released their blood thinner to the public without a corresponding antidote.
Without any available antidote, when a patient taking Xarelto becomes injured and bleeds, doctors cannot easily clot their blood. This can turn a situation with a minor injury into a very dangerous one. At these times, doctors must use extreme, life saving measures such as blood transfusions or surgery to relieve pressure from pooling blood in the brain or spine.
Traditional blood thinners, which require consumers to follow special diets, do this because their available antidote is vitamin K. If these patients take a traditional blood thinner and begin to bleed from injuries, physicians have the ability to treat them with vitamin K, which will counteract the effects of the anticoagulant and allow the patient’s blood to clot. This antidote can quickly become the key to a patient’s survival during an emergency, and Xarelto patients have had none available for over four years now.
Today, Xarelto has become the topic of more than 2,800 federal court lawsuits, in addition to 500 cases which have been consolidated to form a mass tort group by the Court of Common Pleas in Philadelphia, Pennsylvania.
Attorney Joseph Osborne is now working to ensure that everyone who has been negatively affected by Xarelto will have the opportunity to fully explore their legal rights. These people could be entitled to compensation. At this time, Attorney Osborne is offering free consultations for affected individuals.
To request more information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
https://www.pressadvantage.com/story/7686
-
Xarelto Lawsuit Plaintiffs Cite Multiple Studies Which Link Drug To Excessive Bleeding Concerns
Jan 29, 2016 | Blood Thinner Help
By Joseph Osborne
BloodThinnerHelp.com reports on multiple studies which help to support plaintiff arguments in recent Xarelto lawsuits. The results of these studies appear to highlight unsettling links between blood-thinning drug Xarelto and an increased risk for spontaneous and uncontrollable bleeding episodes in those taking it.
Xarelto gained FDA approval in 2011, and was later released to the market as a new-generation anticoagulant. The drug was originally approved to treat patients who had recently undergone knee or hip replacement surgeries to prevent the development of blood clots. This approved use was later expanded to include treatment for patients with atrial fibrillation heart conditions, pulmonary embolism, or deep vein thrombosis, as a preventative measure for strokes and blood clots.
Things quickly changed in the public’s eye, however, as reports of serious adverse health events linked to Xarelto began to surface. Across the U.S., the drug was allegedly connected to the development of blood clots, as well as strokes, pulmonary embolisms, internal and external spontaneous uncontrollable bleeding episodes, and other serious health problems.
Doctors Judy H. Hun and John C. Hwang stepped up to conduct some studies on the drug through their practice, as they had commonly prescribed it to patients and began to get concerned. The doctors indicated that three of their patients had developed “spontaneous vitreous hemorrhage” (or eye bleeding) while taking Xarelto, and so they began to investigate things further. Their study results indicated that the risk of sudden eye bleeds was elevated for patients who had switched from taking a traditional blood thinner to taking Xarelto.
Their second study was conducted between October 1st 2010 and March 31st, 2012. This one evaluated the results of patients from across the nation who were using Xarelto, Pradaxa, and Warfarin (all various brands and types of blood thinners). For this study, doctors collected data from a sample of 46,000 patients: 39,607 warfarin users, 4,907 Pradaxa users, and 1,649 Xarelto users. Research conducted on these patients indicated “as much as a 50% increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin or a more than twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.”
Xarelto lawsuit cases now number over 2,800 in federal court. They have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592, and are being overseen by the Honorable Judge Eldon Fallon in New Orleans, Louisiana. As they await trial, these case numbers are only expected to increase, and they are joined by another 550 cases consolidated to form a mass tort group in Philadelphia, Pennsylvania. Plaintiffs involved in all lawsuits have linked the drug to serious and even fatal bleeding events.
Attorney Joseph Osborne is hoping to assist anyone who used Xarelto and later suffered from health complications. He believes that these individuals may be entitled to legal action and significant compensation, and that everyone deserves the opportunity to fully explore their legal rights and pursue justice. At this time, he is offering complimentary legal consultations to affected individuals.
To obtain the latest information concerning Xarelto lawsuits or ask questions, please call Attorney Osborne at (866) 425-8902.
http://www.hawaiinewsnow.com/story/31091904/xarelto-lawsuit-plaintiffs-cite-multiple-studies-which-link-drug-to-excessive-bleeding-concerns
-
Xarelto Blood Thinner MDL Reaches 2,400 Lawsuits
Jan 22, 2016 | Top Class Actions
By Ashley Vanover
Blood thinner lawsuits alleging patients suffered serious and life-threatening internal bleeding events after using the blood thinner Xarelto show no signs of slowing down, with 2,400 Xarelto lawsuits now pending in the multidistrict litigation.
Plaintiffs similarly allege that the blood thinner can cause dangerous uncontrollable bleeding episodes and that Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals neglected to properly warn about the risks associated with the lack of available antidote for the blood thinner.
According to court documents, the Judicial Panel for Multidistrict Litigation (JPML) noted that as of Dec. 15, 2015, there were 2,400 Xarelto blood thinner lawsuits consolidated for pretrial proceedings in MDL No. 2592 (In Re: Xarelto (Rivaroxaban) Products Liability Litigation, before U.S. District Judge Eldon E. Fallon).
In mid-October, the MDL lawsuits numbered nearly 1,700. Xarelto lawsuit lawyers expect the litigation will continue to grow as time goes on.
Xarelto Lawsuit Allegations
Xarelto was released and approved for sale in 2011 and touted as a superior replacement for Warfarin. Xarelto is used to reduce the risk of blood clots among patients at risk for deep vein thrombosis, pulmonary embolism and those patients at risk for a stroke with atrial fibrillation.
Xarelto blood thinner lawsuits center on allegations that the drug makers failed to warn that the new blood thinner medication lacked an antidote to the drug’s anticlotting mechanism. Without an antidote to clot blood, someone who has Xarelto in their system can be at risk for developing uncontrollable bleeding after even a minor injury.
In these instances, doctors have to use extreme, life-saving measures like blood transfusions or surgery. Even after these attempts, patients can suffer from too much blood loss and die.
Other traditional anticoagulants, like warfarin, do not have this problem. When warfarin patients experience internal bleeding, an antidote in the form of vitamin K can counter the effects of the medication and allow blood to clot.
Many Xarelto lawsuits allege that had patients been made aware of the lack of Xarelto bleeding antidote, they would not have used the medication.
One of these recent lawsuits was filed jointly by nine plaintiffs from across the United States over injuries allegedly sustained in connection to the popular new blood thinner. Injuries include severe internal bleeding and ultimately resulted in the wrongful death of one of the plaintiff’s wife.
“Plaintiffs bring this case against Defendants for damages associated with ingestion of the pharmaceutical drug Xarelto,” the lawsuit states. “Specifically, Plaintiffs suffered various injuries, serious pain and suffering, medical, hospital and surgical expenses, loss of consortium, and/or death and funeral expenses as a direct result of their use of Xarelto.”
Xarelto Multidistrict Litigation
Since December 2014, all federal blood thinner lawsuits filed against Bayer and Johnson & Johnson over the bleeding side effects of Xarelto have been centralized and consolidated before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana as part of an MDL, or multidistrict litigation.
Lawsuits against Bayer and Johnson & Johnson are consolidated in two courts, a multidistrict litigation court in the Eastern District of Louisiana and a mass tort litigation court in Philadelphia.
The MDL in Louisiana now contains over 2,400 federal lawsuits, and the mass tort in Philadelphia contains more than 500 state lawsuits.
Judge Fallon set a series of four bellwether trials scheduled to go trial in Spring 2017.
As Xarelto lawsuit lawyers continue to lay the groundwork for the multidistrict litigation, the number of Xarelto lawsuits filed against the makers of the drug is expected to surpass the current 2,400 cases. If you or your loved one suffered from Xarelto bleeding, an experienced Xarelto lawsuit lawyer can evaluate your case and explain your legal options at no cost.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/300797-xarelto-blood-thinner-lawsuits-reach-2400-in-mdl/
-
Have you or a loved one suffered from Xarelto complications?
Jan 24, 2016 | Law Offices of Ben C. Martin
Xarelto is the brand name for the blood-thinner Rivaroxaban, which is used to prevent blood clotting. It is an anticoagulant that works by blocking certain clotting proteins in blood. This drug is typically used to eliminate blood clotting when a patient is suffering from afflictions such as an irregular heartbeat (atrial fibrillation), after hip or knee replacement surgery, deep vein thrombosis (DVT), and pulmonary embolisms.
It is also used to prevent the blood clots from re-forming. This drug has caused severe injuries in some cases.
Xarelto patients and their families have initiated litigation against the blood thinner manufacturer because of the
complications and serious, disabling, or fatal injuries they have suffered.
These injuries include:Uncontrolled bleeding causing death
Gastrointestinal bleeding
Stroke
Heart attack
Pulmonary embolism
Deep vein thrombosis
Brain hemorrhagingWHAT IS THE HISTORY OF XARELTO, INCLUDING XARELTO BLEEDING COMPLICATIONS?
Xarelto is manufactured by Bayer AG and Janssen Pharmaceuticals, (a division of Johnson & Johnson). The drug was first approved by the FDA in 2011 to treat patients who recently had undergone hip or knee replacement surgeries to prevent blood clots during recovery.
Xarelto’s approval from the FDA was expanded to treat patients with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. However, shortly after its release, Xarelto was found to be dangerous and was linked to hundreds of reports of adverse bleeding events.Many patients in the U.S. said that the drug caused blood clots, strokes, internal bleeding, and uncontrollable bleeding episodes. Research has linked the blood thinner to dangerous and even fatal side effects for patients who use it. Xarelto can cause many types of bleeding, such as the following:
Rectal bleeding
Abdominal bleeding
Hemorrhaging
Bleeding in the brainInternal bleeding can be fatal.
http://bencmartin.thedigitalmarketingonline.com/xarelto-complications-lawyer/
-
Xarelto Bleeding Injury Lawsuit
Jan 24, 2016 | Cory Watson Attorneys
The attorneys at Cory Watson are helping families determine whether the prescription drug Xarelto is responsible for bleeding that shuts down the brain, lungs, kidneys, and other organs. Xarelto use is also linked to deadly hemorrhagic strokes and large hematomas.
The experienced drug injury lawyers at Cory Watson are investigating cases of injuries caused by Xarelto.
What is Xarelto®?
Xarelto® is an anticoagulant, or blood thinner, that’s made by Bayer®, replacing Warfarin® (Coumadin) as the drug of choice for preventing blood clots, protecting people from strokes, and treating irregular heartbeats, specifically atrial fibrillation. Patients taking Xarelto don’t have to get their levels monitored regularly, and the drug does not interact dangerously with certain foods.
What bleeding issues are associated with Xarelto®?
Xarelto side effects and injuries include:
Gastrointestinal Bleeding (GI Bleed)
Hemorrhagic Stroke
Hematomas and Other Bleeding
Patients who have been prescribed Xarelto should consult with their doctor and our experienced attorneys to address the injuries caused by the drug.
http://info.corywatson.com/xarelto-bleeding-injury-lawsuit
-
Lawsuit: Drug Maker Failed to Disclose Xarelto Bleeding Risk
Jan 25, 2016 | American Injury Attorney Group
Drug makers face allegations of negligence after a man died due complications family members claim were associated with the prescription blood thinner Xarelto. Attorneys handling the lawsuit allege that the drug makers were aware of a Xarelto bleeding risk, but failed to properly warn consumers or release all of its findings about the drug’s potentially harmful effects. Affected families are pursuing claims for compensation against the manufacturers of the blood thinner with the assistance of Xarelto attorneys.
If you or a loved one took Xarelto and suffered uncontrolled bleeding or other side effects, contact the American Injury Attorney Group today to learn more about your options. We can answer your questions in a free, confidential, no-obligation consultation, and if you wish to pursue a claim, we can connect you with an affiliated Xarelto lawsuit attorney.
Whether drug makers failed to disclose important research and adequately warn users of the risks associated with the prescription anticoagulant Xarelto will soon be decided in a courtroom. The Madison Record reports that the estate of a victim who allegedly died due to complications related to his use of Xarelto is seeking a settlement from the drug makers to cover associated legal fees and related expenditures.
A representative for Janssen Research & Development touted the drug’s benefits when responding to the allegations made by the plaintiff’s attorneys, arguing that Xarelto’s benefits largely outweigh its associated risks. The lawsuit, filed in September 2015, seeks at least $50,000 from each defendant named in the lawsuit, Janssen Research & Development, Janssen Ortho, Jansen Pharmaceuticals Inc., Bayer Healthcare Pharmaceuticals Inc., Bayer Pharma AG, Bayer Corporation, Bayer Healthcare, and Bayer AG, the website reported.
Injured Patients May Be Entitled to Compensation
Drug manufacturers have a duty to ensure their products are accompanied by full and accurate instructions and warnings to guide prescribing doctors and other health care providers in making treatment decisions. If a drug maker fails to fulfill this duty, it could be held liable in lawsuits for injuries that may result.
Patients who have been injured by Xarelto may be entitled to compensation for damages, including:
Medical expenses
Pain, suffering, and mental anguish
Loss of income or ability to work
If a patient dies from complications after taking Xarelto, his or her family members may be able to pursue claims for their loved one’s wrongful death. Compensation may include:
Pain, suffering, and mental anguish from the loss of a loved one
Loss of financial support of a loved one
Funeral expenses
Affected patients are encouraged to speak with a Xarelto lawsuit attorney to learn more about their rights and remedies.
Contact Us For More Information
If you or a loved one took Xarelto and suffered complications, including internal bleeding, contact the American Injury Attorney Group for more information. You can fill out the form on this page, call us at the number listed at the top of the page, or email us at info@attorneygroup.com.
When you contact us, an attorney will follow up with you to speak with you about your case or answer questions that you might have. There is no cost or obligation to speak with us, and any information you provide will be kept confidential.
Please note that the law limits the time you have to pursue a claim for an injury. If you think you have a case, you should not delay taking action.
See our Frequently Asked Questions page for more information, and contact the American Injury Attorney Group today.
https://attorneygroup.com/blog/xarelto-bleeding-risk/
-
Act Now For Xarelto Suits: Time Running Out
Jan 25, 2016 | Colson Hicks Eidson
We have been keeping you up-to-date on the progress of the Xarelto multidistrict litigations, so we wanted to let you know that time is running out for any victims who have suffered injuries or lost loved ones due to this potentially harmful drug.
Act Now For Xarelto Suits
On September 17th, Judge Eldon Fallon signed a court order to begin selecting dates for the trials that would help speed the legal processes for the thousands of cases against the makers of Xarelto. These trials are called bellwether trials and they are expected to begin during the fall of 2016. That means that the multidistrict litigation could stop accepting new claims soon.
How Will The Xarelto Multidistrict Litigation Work?
There will be four trials that represent the interests of thousands of plaintiffs, and they will take place in Louisiana, Mississippi, and Texas. However, people from all over the country—including Florida natives—will be represented in these cases. They claim that Janssen Pharmaceuticals and Bayer Healthcare had prior knowledge to the fact that Xarelto cannot be counteracted like other anticoagulants but failed to properly warn consumers about the potentially fatal detail.
The makers of prescription medications have a responsibility to not misinform doctors or the public about their medications, and they can be held responsible by anyone injured by the use of those products. Visit our pharmaceutical litigation page for more information, and if you need to act now for the Xarelto multidistrict litigation, contact the attorneys at Colson Hicks Eidson so we can get you started down the path to restitution.
http://www.colson.com/act-now-xarelto-suits-time-running
-
Jan 26, 2016 | Drug Injury Law
Xarelto® is the name under which Janssen Pharmaceuticals, Inc. markets a prescription anticoagulant medication generically called rivaroxaban.
Xarelto is a blood-thinning drug used to reduce the risk of ischemic stroke and blood clots in people with atrial fibrillation not caused by a heart valve problem as well as treatments for deep vein thrombosis (DVT) and pulmonary embolism (PE).
Since coming on the market in 2011 the FDA has received numerous Adverse Event Reports involving the following Xarelto bleeding side effects:
Serious bleeding side effects such as gastrointestinal (GI) bleeds and rectal bleeding
Irreversible life-threatening bleeding events
Trauma-induced atypical bleeding incidents due to lack of effective reversal agent
Hemorrhages such as brain hemorrhage, intracranial hemorrhage, and hemorrhagic stroke
Death as a result of excessive bleeding
Symptoms of these major bleeding complications include:
Coughing up blood
Severe bleeding
Vomiting blood
We point out that these two important facts about these bleeding events:
Xarelto is associated with an increase in the rate of major gastrointestinal (GI) bleeding despite the lower rates of bleeding at other sites; and,
A trend of higher bleeding risk was seen with advancing age.
Other Xarelto Side Effects
In addition, some medical studies have associated Xarelto with an increased risk of these other various side effects:
Drug-induced liver injury (DILI)
Thromboembolic complications such as cerebrovascular accident (CVA)
Heart attack
Myocardial infarction (MI)
Acute coronary syndrome (ACS)
Cardiac bleeds
We are handling personal injury and wrongful death lawsuits involving these Xarelto-related bleeding events as well as the other serious side effects.
http://www.druginjurylaw.com/xarelto-medical-legal-information/
-
New Year Sees 400 More Lawsuits Added to Xarelto MDL
Jan 28, 2016 | LawyersandSettlements.com
By Heidi Turner
The new year has seen more than 400 Xarelto lawsuits added to the multidistrict litigation, with almost 3,000 lawsuits now consolidated for pretrial proceedings. Xarelto lawsuits allege patients given the blood thinner were not properly warned about the increased risk of bleeding events, nor that the newer-generation anticoagulant did not have an approved antidote.
According to court documents, as of January 15, 2016, 2,826 lawsuits were consolidated in MDL 2592 before U.S. District Judge Eldon E. Fallon (In Re: Xarelto (Rivaroxaban) Products Liability Litigation). That’s up from the 2,400 that were consolidated in December. Thousands of lawsuits have been filed against the makers of a variety of newer-generation anticoagulants, alleging patients were put at risk of serious bleeding injuries because they were not properly warned that the drugs did not have antidotes.
Now that the lawsuits have been consolidated, bellwether trials are being scheduled to go ahead. Reports from news releases indicate the first two bellwether trials will be heard on February 6 and March 13 of 2017, with two more reportedly set for April 24 and May 30 of the same year. Forty cases will be chosen for a bellwether pool from which the bellwether cases will be chosen.
Bellwether trials are run to give all sides a better idea of what outcomes subsequent trials are likely to have. Just because bellwether trials are being set, however, does not mean it’s too late for patients to file lawsuits of their own.One such lawsuit, involves Hattie Deville-Goodwin, who died three months after taking Xarelto to treat deep vein thrombosis in her leg. Hattie's granddaughter, Ashlie Fluitt, filed a lawsuit against Janssen Research & Development, alleging Xarelto was to blame for her grandmother’s death.
Warfarin, an older anticoagulant, has an antidote, which critics say makes it safer than the newer anticoagulants. But newer-generation anticoagulants were allegedly marketed as being easier to use than warfarin, because they didn’t require constant blood monitoring. Critics argue that because there is no antidote, monitoring is necessary to ensure patients do not suffer a serious bleeding event, such as a hemorrhage.
The Ashlie Fluitt lawsuit is Ashlie Fluitt v. Janssen Research & Development LLC et al, case number 2:15-cv-05874, in US District Court, Eastern District of Louisiana. In addition to the federal lawsuits, there are also state lawsuits filed in Philadelphia.https://www.lawyersandsettlements.com/articles/xarelto/xarelto-lawsuit-death-bleeding-issue-34-21229.html
-
Xarelto Linked to Internal Bleeding Side Effects
Jan 29, 2016 | Wolf and Pravato
Xarelto (rivaroxaban) is a popular blood thinner, which may be linked with an increased risk of Xarelto internal bleeding.
Janssen, Xarelto’s manufacturer, claims that over seven million people across the globe have been prescribed Xarelto. These patients use Xarelto to prevent dangerous blood clotting complications.
However, some claim that Janssen’s marketing ofXarelto actually misinformed patients and the medical community about the actual safety of the drug. According to Xarelto lawsuits, Janssen deliberately underplayed Xarelto’s safety and efficacy.
Many Xarelto users are now coming forward, claiming that Xarelto is in fact less safe to use than the anticoagulant staple, warfarin.
Xarelto Bleeding Side Effects
Many Xarelto bleeding lawsuits allege that a series of clinical trials have revealed a link between Xarelto and major bleeding events, such as gastrointestinal bleeding.
The studies indicated that bleeding on Xarelto was a greater risk than bleeding on other similar drugs, including generic warfarin. Internal bleeding while on blood thinners may become very dangerous.
Not all side effects of Xarelto are severe or dangerous, and not all users of Xarelto experience side effects. Those who do, however, can be subject to extremely severe and dangerous bleeding issues that cannot be controlled or reversed, given that there is no antidote to counteract Xarelto’s effects.
The lack on an antidote makes Xarelto much more potentially dangerous in the event of a bleeding emergency. It is essential that treatment for internal bleeding be sought immediately. A delay in acquring treatment for internal bleeding could result in death.
Xarelto bleeding lawsuits claim that Janssen was not only aware of these studies and the bleeding risks of Xarelto, but failed to report these major bleeding complications as significant adverse effects. On top of this, the lawsuits allege that Janssen failed to adequately warn consumers and the medical community about the major bleeding risk associated with Xarelto.
Xarelto Bleeding Lawsuits
Xarelto is currently facing hundreds of Xarelto bleeding lawsuits filed for patients who have experienced bleeding on Xarelto. These patients may have experienced gastrointestinal bleeding, hemorrhaging, or other adverse events.
These Xarelto lawsuits claim that the drug makers failed to be completely transparent in the warnings for their product and the Xarelto bleeding side effects, as well as the complications involved in the treatment for internal bleeidng.
These cases also allege that the drug maker should be held accountable for not providing an approved antidote that could reverse the medication’s effects, given the potentially damaging Xarelto side effects many claim to have suffered.
Plaintiffs involved in Xarelto internal bleeding lawsuits allege that Xarelto led directly to severe bleeding, and that the manufacturers failed to adequately warn the public and the medical community about Xarelto’s potential dangers and side effects.
Plaintiffs further allege that drug makers had a responsibility to provide blood level monitoring for users of their drug, especially after recent studies which have suggested blood level monitoring might significantly assist doctors to care for patients who use Xarelto.
If you or someone you know has experienced internal bleeding while on blood thinners, including Xarelto bleeding, you may be able to join a class action Xarelto bleeding lawsuit, file an individual lawsuit, or join the Xarelto MDL.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Xarelto attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Xarelto class action lawsuit is best for you. [In general, Xarelto lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.
https://wolfandpravato.wordpress.com/2016/01/29/xarelto-linked-to-internal-bleeding-side-effects/
-
European Medicines Agency (EMA) Questions Defective Device in Xarelto Trial
Jan 27, 2016 | Schmidt National Law Group
Even the European Medicines Agency (EMA) now questions the reliability of the largest Xarelto clinical trial, the ROCKET AF trial. The study granted the Food and Drugs Administration’s (FDA) approval to the famous blood thinner Xarelto in 2011, and involved more than 14,000 patients to test Xarelto safety on human patients. In this clinical trial, patients with Atrial fibrillation (AFib) were administered either Xarelto or Warfarin to prevent stroke to compare the effectiveness of both these medications. However, last month the EMA found that the results of the ROCKET AF trial may not be so reliable as they initially thought to be. Back in 2011 the FDA regulators warned about some bias found in the clinical trial, however, so it’s not the first time that ROCKET AF’s reliability is questioned.
Xarelto is a dangerous blood thinner used to reduce the risk of pulmonary embolism and deep vein thrombosis and prevent strokes in AFib patients. However, many people suffered severe Xarelto bleeding injuries caused by the dangerous side effects of this medication. The lack of a Xarelto antidote makes even the smallest Xarelto bleeding a potentially life-threatening accident, as doctors have no way to reverse its effects. Almost 3,000 Xarelto bleeding lawsuits have been filed by victims in the whole country, holding Bayer AG and Janssen Pharmaceuticals responsible for the injuries they sustained.
According to EMA’s findings, one of the devices used during the trial was defective, and regulators think that because of this device’s inaccuracies results have been skewed in favor of Xarelto safety. Even the FDA is reviewing the data. The device was used to determine the international normalized ratio (INR), a measurement of the blood’s ability and speed of clotting. The device in question is are the Alere INRatio and INRatio2 PT/INR Monitor system, which was recalled in December 2014. The EMA is investigating whether the device skewed reports may have affected the results of the patients who took Warfarin.
The company’s spokesmen answered by explaining that the real consequences of the defective device may have been overestimated. A single defective device among hundreds used to evaluate the patients’ INRs is, in fact, unlikely to be statistically significant on the overall outcome.
https://xareltolawsuits.net/xarelto-news/european-medicines-agency-ema-questions-defective-device-in-xarelto-trial/
-
Senate Appoints New FDA Chief Amid Xarelto Concerns
Jan 27, 2016 | Righting Injustice
By Jennifer Walker-Journey
The U.S. Senate ha appointed Dr. Robert Califf to serve as the new chief of the Food and Drug Administration (FDA), making him the most powerful health regulator in the world. Califf replaces Margaret Hamburg. He previously served as the Deputy Commissioner.
Califf’s appointment did not come easy. The former cardiologist and medical researcher at Duke University faced tough critics in the Senate, including concerns from Independent party member Bernie Sanders, who is running for the Democratic Party presidential nomination. Sanders questioned Califf’s past payments and stock holdings.
Califf had served as co-chair of the executive committee overseeing clinical trials of the blood thinner Xarelto at the Duke Institute for Clinical Research. Xarelto was being tested as an alternative to the long-used blood thinner warfarin for the prevention of strokes in patients with the common heart rhythm irregularity, atrial fibrillation.
Xarelto’s clinical trials first came under fire during a review by an FDA advisory panel. Medical experts questioned whether the benefits of the drug outweighed Xarelto bleeding risks. The reviewers also wrote that patients taking Xarelto could be “at greater risk of harm from stroke and/or bleeding” than those taking warfarin.
The FDA, which isn’t required to follow the advice of its expert panels, approved the drug in 2011, though the official who issued the FDA’s approval expressed concerns of his own regarding the drug’s safety.
A new red flag regarding Xarelto clinical trials was raised again when it was revealed that blood-testing devices, called INRatio, used during Xarelto testing, had been the subject of two FDA warning letters over concerns that the devices could deliver false test results. The devices were recalled, but researchers continued to use them during Xarelto testing. This data was ultimately used by the FDA and drug regulators in other countries to approve the drug.
This recently uncovered issue has prompted European drug authorities to launch an investigation into Xarelto, and whether data generated from the devices could have impacted the trial results and, if so, to what extent.
Bayer Corp. and Johnson & Johnson unit Janssen Pharmaceuticals face more than 2,000 Xarelto bleeding risk lawsuits in the United States claiming the drug companies did not adequately warn that the drug could cause life threatening uncontrolled bleeding events.
http://www.rightinginjustice.com/news/2016/01/27/senate-appoints-new-fda-chief-amid-xarelto-concerns/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Articles Below
ROCKET AF Trial
Add recipients
Suggested